Hepatitis C Virus Infection and Rheumatic Diseases

Cacoub, Patrice; Commarmond, C.; Sadoun, David; Desbois, Anne Claire

doi:10.1016/j.rdc.2016.09.011

Cited by 22 publications

(3 citation statements)

References 61 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few reports about IFN-free DAA treatment of HCV-associated extrahepatic manifestations, including OLP, mixed cryoglobulinemia, and rheumatic diseases [ 17 , 18 , 26 , 27 ]. We have previously reported the outcomes of HCV-associated OLP in patients who received successful treatment with IFN-free DAAs, using the daclatasvir plus asunaprevir combination therapy [ 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma

Nagao¹,

Nakasone²,

Maeshiro³

et al. 2017

Case Rep Gastroenterol

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF). The 50-year-old patient developed erosive OLP during IFN therapy, with hyperthyroidism at 53 years of age and HCC at 55 years. He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. The patient was treated safely and effectively with LDV/SOF, although it is not known whether the disappearance of OLP resulted from the eradication of HCV or the immunosuppressive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma

Nagao¹,

Nakasone²,

Maeshiro³

et al. 2017

Case Rep Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Despite the effectiveness demonstrated in patients with mixed cryoglobulinemia, the impact of new DAAs on other rheumatologic manifestations is not clear [47]. For fibromyalgia, Younossi et al recently reported major benefits of sofosbuvir-based DAAs on most patient-reported outcomes, including mental and physical fatigue, at week 12 and week 24 post-treatment.…”

Section: Hepatitis Cmentioning

confidence: 99%

Rheumatologic manifestations of hepatic diseases

Fernandes¹,

Dias

Mascarenhas

et al. 2019

aog

View full text Add to dashboard Cite

The course of hepatic diseases may be complicated by a multitude of rheumatologic manifestations, which can complicate the diagnostic approach and alter the natural history of primary liver disease, sometimes worsening prognosis due to associated multiple organ dysfunction. These manifestations can occur in association with a multitude of liver diseases, including viral hepatitis, autoimmune hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, hemochromatosis, or Wilson's disease. It is necessary not only for rheumatologists, but also for other clinicians, to be aware that these atypical manifestations may reflect an undiagnosed hepatic disease. On the other hand, it is crucial that, in a patient with known hepatic disease presenting with rheumatologic symptoms, an accurate distinction be made between the rheumatologic manifestations of hepatic disease and primary rheumatologic disease, since the treatment is often different. This review aims to summarize the current evidence regarding rheumatologic manifestations of hepatic diseases, how to distinguish them from primary rheumatologic disorders, and how to provide adequate management.

show abstract

“…В отдельных случаях, при достижении УВО пациентами с фиброзом печени (F3 по шкале METAVIR) или циррозом печени (F4), возможно существенно снизить риск таких угрожающих для жизни осложнений, как портальная гипер-тензия и печеночная недостаточность. Ввиду развития внепеченочных поражений при HCV-инфекции, успешно проведенная ПВТ с достижением УВО способствует снижению общей смертности среди пациентов с HCV-инфекцией [18,[35][36][37][38].…”

unclassified